Trimodality therapy for patients with stage III non-small-cell lung cancer: A comprehensive surveillance, epidemiology, and end results analysis.

Authors

Vincent P Grzywacz, Beaumont Health Resident
Thomas J Quinn, Beaumont Health
Muayad F Almahariq, Beaumont Health
Zaid A Siddiqui
Sang W Kim, Beaumont Health
Thomas M Guerrero, Beaumont Health
Craig W Stevens, Beaumont Health
Inga S Grills, Beaumont Health

Document Type

Article

Publication Date

5-2-2022

Publication Title

Cancer Treatment and Research Communications

Abstract

PURPOSE: Debate exists regarding the optimal management for patients with stage III non-small-cell lung cancer (NSCLC). Recent inclusion of chemotherapeutic data in the Surveillance, Epidemiology, and End Results (SEER) database has made it possible to identify patients with NSCLC who received chemotherapy. We hypothesized that patients with stage III NSCLC experience improved overall survival from trimodality therapy (TMT) versus definitive chemoradiation therapy (CRT) alone.

MATERIALS AND METHODS: We analyzed the overall survival of stage III NSCLC patients based on the receipt of TMT versus CRT alone. This included crude and adjusted univariate models as well as crude and doubly robust adjusted multivariable analyses, both utilizing propensity score matching and inverse probability of treatment weighting. Factors included in the multivariable analyses included: age, sex, marital status, income, date of diagnosis, primary site, histology, grade, T stage, N stage, and intended treatment. Planned subset analyses were performed for stage III(N2) patients.

RESULTS: Adult patients with stage III NSCLC (N = 9008) from the SEER database were included in our analyses. In our univariate analyses, an overall survival benefit was observed for TMT versus CRT (CrudeHR = 0.58, 95% CI = 0.55-0.61, p < 0.001; AdjHR = 0.58, 95% CI = 0.54-0.61, p < 0.001). This persisted in both crude and doubly robust multivariable analyses (CrudeHR = 0.57, 95% CI = 0.53-0.61, p < 0.001; AdjHR = 0.56, 95% CI = 0.53-0.59, p < 0.001). Patients with stage III(N2) disease also demonstrated a significant benefit to OS with TMT versus CRT alone.

CONCLUSION: The significant difference in overall survival seen with TMT suggests this may be an effective treatment approach for select patients.

Volume

32

First Page

100571

Last Page

100571

Recommended Citation

Grzywacz VP, Quinn TJ, Almahariq MF, Siddiqui ZA, Kim SW, Guerrero TM,et al [Stevens CW, Grills IS] Trimodality therapy for patients with stage III non-small-cell lung cancer: a comprehensive surveillance, epidemiology, and end results analysis. Cancer Treat Res Commun. 2022 May 2;32:100571. doi: 10.1016/j.ctarc.2022.100571. Epub ahead of print. PMID: 35533588.

Comments

Online ahead of print.

DOI

10.1016/j.ctarc.2022.100571

ISSN

2468-2942

PubMed ID

35533588